Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Kai WilleMarvin DumkeNadine WilsdorfParvis SadjadianArtur SchneiderStephanie Jender-BartlingVera KolatzkiAnette HorstmannRaphael MeixnerMarina Jiménez-MuñozChristiane FuchsHans-Joachim TischlerMartin Griesshammer

Published in: European journal of haematology (2024)

The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
acute lymphoblastic leukemia
multiple myeloma
diffuse large b cell lymphoma
squamous cell carcinoma
hodgkin lymphoma
chemotherapy induced